#Sweden #Lund #Enzymatica AB #ColdZyme #Lund Sweden

Enzymatica AB Year-End Report 2024

Enzymatica AB, a Swedish life sciences company known for its innovative products, particularly ColdZyme, has released its year-end report for 2024, showcasing significant movements towards growth, especially in its home market of Sweden. In a year marked by both achievements and challenges, the company reported net sales of SEK 17.2 million in the fourth quarter, an increase from SEK 15.8 million in the same period the previous year.

Financial Overview

The financial results for the year show an operating loss of SEK -13.7 million, slightly improved from SEK -13.8 million in 2023. However, the company acknowledged the pressures on cash flow, totaling SEK -20.6 million compared to SEK -2.6 million in the previous year. For the entire 2024 period, net sales reached SEK 45.6 million, a decrease from SEK 50.9 million in 2023. The overall operating result was reported as SEK -52.1 million, reflecting the ongoing commercial development efforts.

Despite these challenges, the company’s cash position remains relatively strong, ending the year with net cash of SEK 73.0 million, a significant rebound from the previous year's negative cash position of SEK -17.7 million. This financial resilience provides a solid foundation for Enzymatica's plans for future international initiatives.

CEO's Insights

CEO Claus Egstrand emphasized the gains made in the Swedish market, stating, "Throughout the year, we have made significant commercial progress in ColdZyme's home market. Sales and market share data from pharmacies confirm this positive development. We have created the right conditions for future growth by enhancing our sales organization."

Egstrand highlighted the expected impact of an independent clinical study which is vital for the company's growth strategy. He expressed optimism about 2025, noting that the research will facilitate the introduction of ColdZyme into new markets and potentially boost sales significantly.

Key Developments

While the report indicated no significant events during the quarter, a strategic focus on strengthening the sales organization was highlighted. This included the recruitment of a new Senior Sales & Marketing Director and a Director of Strategic Partnerships, crucial roles aimed at fostering market expansion.

Promotional strategies included ColdZyme’s advertising campaign on TV4 and its presence on YouTube during peak cold seasons, aimed at increasing brand visibility and consumer engagement. Furthermore, the launch of new MDR packaging in Sweden was rolled out, intended to provide clearer information to consumers, marking a commitment to enhance customer experience and compliance with market regulations.

Future Growth Plans

With the foundation laid in 2024, Enzymatica is poised to navigate the complexities of international growth successfully. The company is committed to sustaining its research and development efforts while nurturing its core markets. The optimism of the CEO and the strategic initiatives in place signal a focused direction towards expanding ColdZyme’s market share internationally.

The full year-end report, which includes detailed financial metrics and strategic insights, is available on Enzymatica’s Investor Relations page. Shareholders and interested parties are encouraged to review the findings for a comprehensive understanding of the company’s current position and future outlook.

Overall, 2024 has laid the groundwork for an exciting 2025, and Enzymatica AB is ready to seize growth opportunities, aspiring to impact the global market with its innovative health solutions.